The Insourcing Dilemma: Greater Control, Greater Complexity

The Insourcing Dilema

The math on hub outsourcing is changing. But so is the difficulty of doing it right. 

The pull to bring hub functions in-house has become one of the most consequential shifts in the commercialization playbook, and the reasons aren’t the ones people were talking about even two years ago. It’s not just about data. It’s about IRA readiness, patient journey ownership, the accelerating complexity of affordability programs, and a growing conviction that the strategic core of the patient experience shouldn’t be sitting in someone else’s tech stack. 

The Numbers Behind the Shift 

The 2026 Cardinal Health / studioID benchmark report, based on an online survey conducted by BioPharma Dive from December 22, 2025, to January 16, 2026, with 200 executives from biopharmaceutical manufacturing companies, is one of the clearest snapshots we have of what’s happening. And the trend line is unmistakable. 

In 2026, 63% of survey respondents report having hybrid hubs. Although that’s a dip from the 79% in the 2024 survey, it’s still a dominant model in the current hub environment. More telling is what’s happening at the edges. The fully insourced hub is up 12 percentage points from 2024, and the fully outsourced hub is up 5 percentage points from 2024. 

Read that again. The middle is shrinking. Manufacturers are moving to the poles, either owning more of the hub or handing more of it off, and the biggest gainer is full insourcing. 

The leadership pressure is real, too. 39% of biopharma executives say they’ve felt leadership pressure to move at least some hub functions in-house, up from 28% in 2024. 

What’s Actually Driving This? The Motivators Have Evolved. 

Two years ago, when this trend was first showing up in earnest, the answer was almost always “data.” Data control, data access, data ownership. Everyone wanted to control the pipe. That was the whole conversation. That’s not what the 2026 data shows. 

In 2024, data control and access control were the primary drivers of insourcing. But in 2026, motivators have changed. As organizations build their bench of talent in a dynamic healthcare environment, they’re looking more toward internal expertise and self-sufficiency as their top reasons to insource. Top motivators to insource: 65% internal expertise, 57% ability to be self-sufficient. In 2024, the top motivators were 46% data control and 55% access control. 

That shift matters. It’s the difference between “we want to own the data” and “we want to own the capability.” Those may sound similar, but they are far from it. 

Owning the data is a governance problem. Owning the capability is an organizational transformation problem. One requires better contracts and integrations. The other requires building teams, hiring specialized talent, standing up new technology, and doing all of it while your existing programs keep running for the patients who depend on them. 

The External Pressures Aren’t Getting Easier 

Any conversation about insourcing has to include the elephant in the room: the Inflation Reduction Act and everything that flows downstream from it. Medicare price negotiation, the Part D redesign, the out-of-pocket cap, the M3P smoothing program, the growing scrutiny of copay support. All of it is changing what “patient affordability” even means. 

When respondents were asked what they saw as the biggest threat to patient services innovation over the next one to two years, the answers were sobering. 43% cited external forces, such as payer demands or regulations. 35% cited internal forces, such as a reluctance to embrace new technologies or processes. 22% weren’t sure. 

Nearly half of the market thinks the biggest threat to their patient support programs is coming from outside their control. That’s the environment manufacturers are choosing to insource into. 

There’s a version of this argument that says insourcing is actually the smart response to that pressure. If regulation is going to reshape the affordability landscape every eighteen months, you want the ability to pivot fast. You don’t want to be waiting on a vendor’s release cycle to update your patient experience. 

But there’s another version that says insourcing at this moment is exactly the wrong move, because the regulatory whiplash will consume your internal team’s bandwidth before it can build sustainable capability. 

The Pitfalls, and Why They’re Not the Ones You’d Expect 

  1. The Data Governance Problem Nobody Wants to Talk About: When you insource, you inherit the data. All of it. If your organization doesn’t already have mature data governance, HIPAA compliance frameworks that extend beyond the compliance department, and a real answer to “who owns this data internally,” you’re going to have problems. Anyone can own data. Managing it well takes real infrastructure.
  2. Staffing: The Talent Isn’t Just Sitting There Waiting for You: The number-one motivator in the 2026 survey, at 65%, is “internal expertise.” But here’s the awkward truth: the specialized expertise that runs a functional hub is a distinct discipline. It doesn’t map cleanly onto commercial operations or medical affairs or market access. The people who are good at it tend to work for hub vendors, because that’s where the career path has traditionally been. Insourcing means hiring those people. Or retraining internal team members. Or, most commonly, some combination that leaves you understaffed and overpromised for the first twelve to eighteen months of the transition. 
  3. Tech Integration: Where “Standing Up a CRM” Turns Into a Two-Year Odyssey: Standing up a manufacturer-owned CRM can provide greater control over the patient experience, but it still requires coordination with PBM data and processes, including dispense data, PA status, and copay accumulator logic. Ensuring seamless data exchange across these stakeholders may remain a challenge.
  4. The Consolidation Question: Consolidation is often the necessary first step for manufacturers moving toward hybrid or insourced hub models. When you consolidate from four vendors to one before you insource, you’ve concentrated your operational dependency at exactly the moment you’re trying to reduce it. If that consolidation doesn’t go well, or if the surviving vendor isn’t equipped for the hybrid model you’re building toward, you’ve created a single point of failure right in the middle of a strategic transformation.

The Honest Assessment 

Here’s where I land after seeing this play out with a lot of clients. 

Insourcing is strategically defensible for the right manufacturer. If you have the scale, technology, talent, and organizational stability to support it, there are real reasons to bring certain capabilities in-house. But the operational reality is much harder than the strategy sounds on paper. It’s a multi-year transformation, and it tends to require a lot more organizational energy and executive attention than people expect going in. 

That’s why I wouldn’t discount hybrid. Manufacturers can own the things that are truly strategic, patient journey design, brand experience, data and insights, without necessarily needing to own every piece of the machinery underneath it. 

And if the middle really is shrinking, I don’t think that means hybrid failed. I think it means the definition of hybrid is getting smarter. Manufacturers are getting clearer about where ownership actually creates value and where a specialized partner can still do the job better or more efficiently. 

To me, that’s what a maturing market looks like.